source
- Precision strategies help de-risk rare disease therapy launchesCommercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
- FDA advisory panel backs Moderna's experimental flu vaccine in adults 50-64, supports accelerated review for 65+The FDA's advisory committee voted unanimously to recommend Moderna's mRNA-1010 flu vaccine for adults aged 50 to 64, and also found it beneficial for those 65 and older. The 9-0 vote allows Moder…